Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.

{"article_title":"Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.","author":"Qi, Litong , Shen, Hua , Chai, Meng , Chen, Beijian , He, Yongming , Shi, Xiaoxia , Lian, Qiufang , Zhao, Wang , Qu, Yanling , Qian, Lei , Zhang, Jianwei , Li, Haoyu , Zhou, Yujie , Huo, Yong","journal_title":"Cardiovascular diabetology","issn":"1475-2840 ; Electronic","isbn":"","publication_date":"20250703","volume":"24","issue":"1","first_page":"264","page_count":"","accession_number":"40611077","doi":"10.1186\/s12933-025-02816-3","publisher":"BioMed Central","doctype":"Clinical Trial","subjects":"Cardiology ","interest_area":["Endocrinology"," Cardiology"," Internal\/Family Medicine"],"abstract":"Declarations. Ethics approval and consent to participate: All studies adhered to the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study protocols received approval from the institutional review boards or independent ethics committees, and all participants provided written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=40611077&authtype=shib&custid=ns346513"}